Cargando…
Predictive Factors of Neutropenia in HIV-Infected Patients with Malignancy Receiving Chemotherapy or Radiotherapy
OBJECTIVE: To determine the predictive factors of neutropenia in human immunodeficiency virus (HIV)-infected patients with malignancy receiving chemotherapy (CMT) or radiotherapy (RT). MATERIALS AND METHODS: The author conducted a retrospective study on HIV-infected patients with malignancy receivin...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
West Asia Organization for Cancer Prevention
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9272631/ https://www.ncbi.nlm.nih.gov/pubmed/35225455 http://dx.doi.org/10.31557/APJCP.2022.23.2.445 |
_version_ | 1784744909092159488 |
---|---|
author | Suthepwanon, Apisada Uttasri, Patcharin Boonyagars, Lakkana |
author_facet | Suthepwanon, Apisada Uttasri, Patcharin Boonyagars, Lakkana |
author_sort | Suthepwanon, Apisada |
collection | PubMed |
description | OBJECTIVE: To determine the predictive factors of neutropenia in human immunodeficiency virus (HIV)-infected patients with malignancy receiving chemotherapy (CMT) or radiotherapy (RT). MATERIALS AND METHODS: The author conducted a retrospective study on HIV-infected patients with malignancy receiving CMT or RT at Vajira Hospital, Navamindradhiraj University, Thailand, from January 1, 2013 to December 31, 2017. Baseline demographic characteristics, HIV disease data, and cancer data were collected. RESULTS: A total of 210 courses of CMT, concurrent chemoradiation therapy (CCRT), or RT treatments were administered to 39 HIV-infected patients with malignancy. Neutropenia occurred in 51 (24.3%) of the 210 treatment courses in 23 (60%) patients. Multivariable analysis revealed that HIV-infected patients with malignancy who received CMT or CCRT (hazard ratio [HR] 10.83, 95% confidence interval [CI] 1.36–86.05, p = 0.024) and those who received over five cycles of CMT (HR 5.25, 95% CI 1.10–26.01, p = 0.037) were independently associated with neutropenia. CONCLUSION: Receiving CMT or CCRT and receiving more than five cycles of CMT are risk factors for neutropenia in HIV-infected patients with malignancy. |
format | Online Article Text |
id | pubmed-9272631 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | West Asia Organization for Cancer Prevention |
record_format | MEDLINE/PubMed |
spelling | pubmed-92726312022-07-14 Predictive Factors of Neutropenia in HIV-Infected Patients with Malignancy Receiving Chemotherapy or Radiotherapy Suthepwanon, Apisada Uttasri, Patcharin Boonyagars, Lakkana Asian Pac J Cancer Prev Research Article OBJECTIVE: To determine the predictive factors of neutropenia in human immunodeficiency virus (HIV)-infected patients with malignancy receiving chemotherapy (CMT) or radiotherapy (RT). MATERIALS AND METHODS: The author conducted a retrospective study on HIV-infected patients with malignancy receiving CMT or RT at Vajira Hospital, Navamindradhiraj University, Thailand, from January 1, 2013 to December 31, 2017. Baseline demographic characteristics, HIV disease data, and cancer data were collected. RESULTS: A total of 210 courses of CMT, concurrent chemoradiation therapy (CCRT), or RT treatments were administered to 39 HIV-infected patients with malignancy. Neutropenia occurred in 51 (24.3%) of the 210 treatment courses in 23 (60%) patients. Multivariable analysis revealed that HIV-infected patients with malignancy who received CMT or CCRT (hazard ratio [HR] 10.83, 95% confidence interval [CI] 1.36–86.05, p = 0.024) and those who received over five cycles of CMT (HR 5.25, 95% CI 1.10–26.01, p = 0.037) were independently associated with neutropenia. CONCLUSION: Receiving CMT or CCRT and receiving more than five cycles of CMT are risk factors for neutropenia in HIV-infected patients with malignancy. West Asia Organization for Cancer Prevention 2022-02 /pmc/articles/PMC9272631/ /pubmed/35225455 http://dx.doi.org/10.31557/APJCP.2022.23.2.445 Text en https://creativecommons.org/licenses/by-nc/4.0/This work is licensed under a Creative Commons Attribution-Non Commercial 4.0 International License. https://creativecommons.org/licenses/by-nc/4.0/ |
spellingShingle | Research Article Suthepwanon, Apisada Uttasri, Patcharin Boonyagars, Lakkana Predictive Factors of Neutropenia in HIV-Infected Patients with Malignancy Receiving Chemotherapy or Radiotherapy |
title | Predictive Factors of Neutropenia in HIV-Infected Patients with Malignancy Receiving Chemotherapy or Radiotherapy |
title_full | Predictive Factors of Neutropenia in HIV-Infected Patients with Malignancy Receiving Chemotherapy or Radiotherapy |
title_fullStr | Predictive Factors of Neutropenia in HIV-Infected Patients with Malignancy Receiving Chemotherapy or Radiotherapy |
title_full_unstemmed | Predictive Factors of Neutropenia in HIV-Infected Patients with Malignancy Receiving Chemotherapy or Radiotherapy |
title_short | Predictive Factors of Neutropenia in HIV-Infected Patients with Malignancy Receiving Chemotherapy or Radiotherapy |
title_sort | predictive factors of neutropenia in hiv-infected patients with malignancy receiving chemotherapy or radiotherapy |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9272631/ https://www.ncbi.nlm.nih.gov/pubmed/35225455 http://dx.doi.org/10.31557/APJCP.2022.23.2.445 |
work_keys_str_mv | AT suthepwanonapisada predictivefactorsofneutropeniainhivinfectedpatientswithmalignancyreceivingchemotherapyorradiotherapy AT uttasripatcharin predictivefactorsofneutropeniainhivinfectedpatientswithmalignancyreceivingchemotherapyorradiotherapy AT boonyagarslakkana predictivefactorsofneutropeniainhivinfectedpatientswithmalignancyreceivingchemotherapyorradiotherapy |